BioCentury | Apr 21, 2020
Product Development

April 20 Quick Takes: Top-line data for BMS, Idorsia and Ascendis; plus Otsuka-Esperion, Regeneron and more

BMS combo meets in Phase III for malignant pleural mesothelioma  Bristol Myers Squibb Co. (NYSE:BMY) said top-line results from the Phase III CheckMate -743 trial showed a combination of anti-PD-1 mAb Opdivo nivolumab and anti-CTLA4...
BioCentury | Apr 10, 2020
Product Development

April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

Award swells to $1.2B, plus royalties, in Kite CAR T suit  Bristol Myers Squibb Co. (NYSE:BMY) and Memorial Sloan Kettering Cancer Center will receive at least $1.2 billion from Gilead Sciences Inc. (NASDAQ:GILD) after a...
BioCentury | Mar 13, 2020
Product Development

March 12 Quick Takes: WuXi AppTec’s Wuhan site back online; plus SOX relief, AZ, BMS, Nicox-Ocumesion, Tyligand-Context

All WuXi AppTec Chinese sites operating  WuXi AppTec Co. Ltd. (Shanghai:603259; HKEX:2359) said it has resumed operations at its Wuhan facility, which provides discovery chemistry services. The company has now restarted operations at all its...
BC Extra | Feb 1, 2020
Company News

Alnylam’s Givlaari, Novo’s Rybelsus among CHMP’s latest recommendations

Among a series of recommendations issued Friday, EMA’s CHMP backed approval of what would be Alnylam’s second approved RNAi drug in the EU, as well as an oral diabetes therapy that Novo Nordisk is relying...
BC Extra | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy  Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive rights to develop and commercialize tapinarof in Japan for dermatology indications including psoriasis and atopic dermatitis. The...
BC Extra | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

Cancer play Treadwell debuted Monday as Tio Bioventures’s first portfolio company with $27 million in seed funding and a pair of differentiated oral small molecules that are already in the clinic. Founded last year, Tio...
BC Extra | Dec 16, 2019
Financial News

Immuneering to bolster cancer pipeline, expand services unit with $17M series A

Eleven-year-old Immuneering Corp. has raised its first venture round as it gears up to send its inaugural program to the clinic to treat cachexia in cancer patients and extensively expand its pipeline. Some of the...
BC Extra | Nov 22, 2019
Clinical News

Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

Tecentriq continues to carve out a niche in the crowded PD-1/PD-L1 space as new survival data for the drug in the combination with Avastin in hepatocellular carcinoma pave the way for the regimen to become...
BC Extra | Nov 5, 2019
Clinical News

Regeneron’s Libtayo shows response rate in line with Keytruda’s in first-line NSCLC

Interim data from a Phase III study showed that the response rate to Regeneron’s Libtayo among first-line lung cancer patients was comparable to the rate in the label of competing PD-1 inhibitor Keytruda. If upcoming...
BC Extra | Oct 28, 2019
Clinical News

AZ triplet joins race to challenge Keytruda in 1L NSCLC

AstraZeneca has become the third company now to report positive results for a triplet immunotherapy and chemo regimen to treat first-line non-small cell lung cancer, but the jury is still out on how large the...
Items per page:
1 - 10 of 700